Skip to main content
. Author manuscript; available in PMC: 2015 Jan 14.
Published in final edited form as: Oncogene. 2008 Aug 4;27(49):6365–6375. doi: 10.1038/onc.2008.250

Figure 3.

Figure 3

AZD0530 inhibits cell proliferation through β-catenin, ERK1/2 and GSK3β-mediated cyclin D1 and c-myc regulation. (a) DU145 and PC3 cells treated with AZD0530 shows dose-dependent decreases in levels of cyclin D1 and c-Myc. Corresponding rebound of phospho-Src and c-Myc is seen over time. (b) Cyclin D1 and c-Myc transcript levels decreased following 4 μM AZD0530 treatment. (c) AZD0530 treatment did not inhibit signal and transducer of transcription 3 activation after 30 min but downregulated β-catenin after 24 h (top). DU145 and PC3 treated with 4 μM of AZD0530 for 12 h shows decreased binding of β-catenin to cyclin D1 and c-Myc promoter regions (bottom). (d) AZD0530 inhibited ERK1/2 and GSK3β phosphorylation in DU145 and AKT and GSK3β phosphorylation in PC3 after 30 min.